Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications

被引：24

作者：

Smolders, E. J. ^{[1
]}

de Kanter, C. T. M. M. ^{[2
]}

de Knegt, R. J. ^{[3
]}

van der Valk, M. ^{[4
]}

Drenth, J. P. H. ^{[5
]}

Burger, D. M. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Pharm, Geert Grooteplein Zuid 10, NL-6525 GA Nijmegen, Netherlands

[2] Univ Med Ctr Utrecht, Dept Pharm, Utrecht, Netherlands

[3] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands

[4] Ctr Infect & Immun Amsterdam CINIMA, Acad Med Ctr, Div Infect Dis, Amsterdam, Netherlands

[5] Radboud Univ Nijmegen Med Ctr, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands

来源：

CLINICAL PHARMACOKINETICS | 2016年 / 55卷 / 12期

关键词：

CHRONIC HEPATITIS-C; HEALTHY-VOLUNTEERS; PHARMACOKINETICS; INFECTION; RITONAVIR; DEPRESSION; THERAPY;

D O I：

10.1007/s40262-016-0407-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Treatment options for chronic hepatitis C virus (HCV) infection have drastically changed since the development and licensing of new potent direct-acting antivirals (DAAs). The majority of DAAs are extensively metabolized by liver enzymes and have the ability to influence cytochrome P450 (CYP) enzymes. Additionally, these DAAs are both substrates and inhibitors of drug transporters, which makes the DAAs both possible victims or perpetrators of drug-drug interactions (DDIs). There is a high prevalence of mental illnesses such as depression or psychosis in HCV-infected patients; therefore, psychoactive medications are frequently co-administered with DAAs. The majority of these psychoactive medications are also metabolized by CYP enzymes but remarkably little information is available on DDIs between psychoactive medications and DAAs. Hence, the aim of this review is to provide an overview of the interaction mechanisms between DAAs and psychoactive agents. In addition, we describe evidenced-based interactions between DAAs and psychoactive drugs and identify safe options for the simultaneous treatment of mental illnesses and chronic HCV infection.

引用

页码：1471 / 1494

页数：24

共 50 条

[21] Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients [J].

Poizot-Martin, Isabelle ;

Naqvi, Alissa ;

Obry-Roguet, Veronique ;

Valantin, Marc-Antoine ;

Cuzin, Lise ;

Billaud, Eric ;

Cheret, Antoine ;

Rey, David ;

Jacomet, Christine ;

Duvivier, Claudine ;

Pugliese, Pascal ;

Pradat, Pierre ;

Cotte, Laurent .

PLOS ONE, 2015, 10 (10)

[22] Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir [J].

Badri, Prajakta S. ;

Dutta, Sandeep ;

Wang, Haoyu ;

Podsadecki, Thomas J. ;

Polepally, Akshanth R. ;

Khatri, Amit ;

Zha, Jiuhong ;

Chiu, Yi-Lin ;

Awni, Walid M. ;

Menon, Rajeev M. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (01) :105-114

[23] Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir [J].

Shebley, Mohamad ;

Liu, Jinrong ;

Kavetskaia, Olga ;

Sydor, Jens ;

de Morais, Sonia M. ;

Fischer, Volker ;

Nijsen, Marjoleen J. M. A. ;

Bow, Daniel A. J. .

DRUG METABOLISM AND DISPOSITION, 2017, 45 (07) :755-764

[24] A Clinician's Guide to Drug-Drug Interactions With Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Viral Infection [J].

Dick, Travis B. ;

Lindberg, Lance S. ;

Ramirez, Debra D. ;

Charlton, Michael R. .

HEPATOLOGY, 2016, 63 (02) :634-643

[25] The clinical significance of drug interactions between dermatological and psychoactive medications [J].

Frew, John W. .

DERMATOLOGIC THERAPY, 2014, 27 (01) :1-11

[26] Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir [J].

Polepally, Akshanth R. ;

Dutta, Sandeep ;

Hu, Beibei ;

Podsadecki, Thomas J. ;

Awni, Walid M. ;

Menon, Rajeev M. .

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (04) :269-277

[27] Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect [J].

Smolders, E. J. ;

Smit, C. ;

de Kanter, C. T. M. M. ;

Dofferhoff, A. S. M. ;

Arends, J. E. ;

Brinkman, K. ;

Rijnders, B. ;

van der Valk, M. ;

Reiss, P. ;

Burger, D. M. .

HIV MEDICINE, 2018, 19 (03) :216-226

[28] Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review [J].

Sarparast, Aryan ;

Thomas, Kelan ;

Malcolm, Benjamin ;

Stauffer, Christopher S. .

PSYCHOPHARMACOLOGY, 2022, 239 (06) :1945-1976

[29] Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review [J].

Aryan Sarparast ;

Kelan Thomas ;

Benjamin Malcolm ;

Christopher S. Stauffer .

Psychopharmacology, 2022, 239 :1945-1976

[30] Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury? [J].

Mishra, Poonam ;

Chen, Minjun .

GASTROENTEROLOGY, 2017, 152 (06) :1270-1274

← 1 2 3 4 5 →